Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G1/S transition

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 76-84

  Kogure, Masaharu ^a,b   Takawa, Masashi ^a,b   Cho, Hyun Soo ^c   Toyokawa, Gouji ^a   Hayashi, Kazuyuki ^a   Tsunoda, Tatsuhiko ^d   Kobayashi, Takaaki ^b   Daigo, Yataro ^e   Sugiyama, Masanori ^b   Atomi, Yutaka ^b   Nakamura, Yusuke ^a,f   Hamamoto, Ryuji ^a,f  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d RIKEN   (Japan)

^e SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

G1 S transition; Histone demethylase; Human carcinogenesis; JMJD2A

Indexed keywords

ADAM 12 PROTEIN; ADAM PROTEIN; BROXURIDINE; HISTONE H3; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE FUNCTION; GENE OVEREXPRESSION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; JUMONJI DOMAIN CONTAINING 2A GENE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT;

ADULT; AGED; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RNA, SMALL INTERFERING; S PHASE; URINARY BLADDER NEOPLASMS;

EID: 84878972592     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.009     Document Type: Article

References (58)

1. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., Casero R.A. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
2. Tsukada Y., Fang J., Erdjument-Bromage H., Warren M.E., Borchers C.H., Tempst P., Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006, 439:811-816.
3. Hayami S., Kelly J.D., Cho H.S., Yoshimatsu M., Unoki M., Tsunoda T., Field H.I., Neal D.E., Yamaue H., Ponder B.A., Nakamura Y., Hamamoto R. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 2011, 128:574-586.
4. Metzger E., Wissmann M., Yin N., Muller J.M., Schneider R., Peters A.H., Gunther T., Buettner R., Schule R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005, 437:436-439.
5. Clifton I.J., McDonough M.A., Ehrismann D., Kershaw N.J., Granatino N., Schofield C.J. Structural studies on 2-oxoglutarate oxygenases and related double-stranded beta-helix fold proteins. J. Inorg. Biochem. 2006, 100:644-669.
6. Schneider J., Shilatifard A. Histone demethylation by hydroxylation: chemistry in action. ACS Chem. Biol. 2006, 1:75-81.
7. Cloos P.A., Christensen J., Agger K., Maiolica A., Rappsilber J., Antal T., Hansen K.H., Helin K. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006, 442:307-311.
8. Fodor B.D., Kubicek S., Yonezawa M., O'Sullivan R.J., Sengupta R., Perez-Burgos L., Opravil S., Mechtler K., Schotta G., Jenuwein T. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev. 2006, 20:1557-1562.
9. Klose R.J., Yamane K., Bae Y., Zhang D., Erdjument-Bromage H., Tempst P., Wong J., Zhang Y. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature 2006, 442:312-316.
10. Whetstine J.R., Nottke A., Lan F., Huarte M., Smolikov S., Chen Z., Spooner E., Li E., Zhang G., Colaiacovo M., Shi Y. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 2006, 125:467-481.
11. Yamane K., Toumazou C., Tsukada Y., Erdjument-Bromage H., Tempst P., Wong J., Zhang Y. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 2006, 125:483-495.
12. Katoh M. Identification and characterization of JMJD2 family genes in silico. Int. J. Oncol. 2004, 24:1623-1628.
13. Shin S., Janknecht R. Diversity within the JMJD2 histone demethylase family. Biochem. Biophys. Res. Commun. 2007, 353:973-977.
14. Wissmann M., Yin N., Muller J.M., Greschik H., Fodor B.D., Jenuwein T., Vogler C., Schneider R., Gunther T., Buettner R., Metzger E., Schule R. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat. Cell Biol. 2007, 9:347-353.
15. Wallard M.J., Pennington C.J., Veerakumarasivam A., Burtt G., Mills I.G., Warren A., Leung H.Y., Murphy G., Edwards D.R., Neal D.E., Kelly J.D. Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br. J. Cancer 2006, 94:569-577.
16. Olsburgh J., Harnden P., Weeks R., Smith B., Joyce A., Hall G., Poulsom R., Selby P., Southgate J. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J. Pathol. 2003, 199:41-49.
17. Cho H.S., Suzuki T., Dohmae N., Hayami S., Unoki M., Yoshimatsu M., Toyokawa G., Takawa M., Chen T., Kurash J.K., Field H.I., Ponder B.A., Nakamura Y., Hamamoto R. Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 2011, 71:1-6.
18. Kikuchi T., Daigo Y., Katagiri T., Tsunoda T., Okada K., Kakiuchi S., Zembutsu H., Furukawa Y., Kawamura M., Kobayashi K., Imai K., Nakamura Y. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003, 22:2192-2205.
19. Kitahara O., Furukawa Y., Tanaka T., Kihara C., Ono K., Yanagawa R., Nita M.E., Takagi T., Nakamura Y., Tsunoda T. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res. 2001, 61:3544-3549.
20. Gilot D., Le Meur N., Giudicelli F., Le Vee M., Lagadic-Gossmann D., Theret N., Fardel O. RNAi-based screening identifies kinases interfering with dioxin-mediated up-regulation of CYP1A1 activity. PLoS One 2011, 6:e18261.
21. Meng W., Mushika Y., Ichii T., Takeichi M. Anchorage of microtubule minus ends to adherens junctions regulates epithelial cell-cell contacts. Cell 2008, 135:948-959.
22. Hamamoto R., Furukawa Y., Morita M., Iimura Y., Silva F.P., Li M., Yagyu R., Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 2004, 6:731-740.
23. Takawa M., Masuda K., Kunizaki M., Daigo Y., Takagi K., Iwai Y., Cho H.S., Toyokawa G., Yamane Y., Maejima K., Field H.I., Kobayashi T., Akasu T., Sugiyama M., Tsuchiya E., Atomi Y., Ponder B.A., Nakamura Y., Hamamoto R. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 2011, 102:1298-1305.
24. Cho H.S., Shimazu T., Toyokawa G., Daigo Y., Maehara Y., Hayami S., Ito A., Masuda K., Ikawa N., Field H.I., Tsuchiya E., Ohnuma S., Ponder B.A., Yoshida M., Nakamura Y., Hamamoto R. Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. Nat. Commun. 2012, 3:1072.
25. Toyokawa G., Masuda K., Daigo Y., Cho H.S., Yoshimatsu M., Takawa M., Hayami S., Maejima K., Chino M., Field H.I., Neal D.E., Tsuchiya E., Ponder B.A., Maehara Y., Nakamura Y., Hamamoto R. Minichromosome maintenance protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Mol. Cancer 2011, 10:65.
26. Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25:1754-1760.
27. Zhang Y., Liu T., Meyer C.A., Eeckhoute J., Johnson D.S., Bernstein B.E., Nusbaum C., Myers R.M., Brown M., Li W., Liu X.S. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008, 9:R137.
28. J. Feng, T. Liu, Y. Zhang, Using MACS to identify peaks from ChIP-Seq data, Curr. Protoc. Bioinf. (2011) (Chapter 2, Unit 2 14).
29. Kadota K., Nishiyama T., Shimizu K. A normalization strategy for comparing tag count data. Algorithms Mol. Biol. 2012, 7:5.
30. Jacobsen J., Wewer U.M. Targeting ADAM12 in human disease: head, body or tail?. Curr. Pharm. Des. 2009, 15:2300-2310.
31. Carl-McGrath S., Lendeckel U., Ebert M., Roessner A., Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int. J. Oncol. 2005, 26:17-24.
32. Kornberg L.J., Villaret D., Popp M., Lui L., McLaren R., Brown H., Cohen D., Yun J., McFadden M. Gene expression profiling in squamous cell carcinoma of the oral cavity shows abnormalities in several signaling pathways. Laryngoscope 2005, 115:690-698.
33. Markowski J., Oczko-Wojciechowska M., Gierek T., Jarzab M., Paluch J., Kowalska M., Wygoda Z., Pfeifer A., Tyszkiewicz T., Jarzab B., Niedzielska I., Borgiel-Marek H. Gene expression profile analysis in laryngeal cancer by high-density oligonucleotide microarrays. J. Physiol. Pharmacol. 2009, 60(Suppl. 1):57-63.
34. Mino N., Miyahara R., Nakayama E., Takahashi T., Takahashi A., Iwakiri S., Sonobe M., Okubo K., Hirata T., Sehara A., Date H. A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma. J. Surg. Oncol. 2009, 100:267-272.
35. Roepman P., Wessels L.F., Kettelarij N., Kemmeren P., Miles A.J., Lijnzaad P., Tilanus M.G., Koole R., Hordijk G.J., van der Vliet P.C., Reinders M.J., Slootweg P.J., Holstege F.C. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat. Genet. 2005, 37:182-186.
36. Kveiborg M., Albrechtsen R., Couchman J.R., Wewer U.M. Cellular roles of ADAM12 in health and disease. Int. J. Biochem. Cell Biol. 2008, 40:1685-1702.
37. Rao V.H., Kandel A., Lynch D., Pena Z., Marwaha N., Deng C., Watson P., Hansen L.A. A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion. Oncogene 2011, 31:2888-2898.
38. Walz A., Burgener R., Car B., Baggiolini M., Kunkel S.L., Strieter R.M. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J. Exp. Med. 1991, 174:1355-1362.
39. Matsuo Y., Raimondo M., Woodward T.A., Wallace M.B., Gill K.R., Tong Z., Burdick M.D., Yang Z., Strieter R.M., Hoffman R.M., Guha S. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int. J. Cancer 2009, 125:1027-1037.
40. Park J.Y., Park K.H., Bang S., Kim M.H., Lee J.E., Gang J., Koh S.S., Song S.Y. CXCL5 overexpression is associated with late stage gastric cancer. J. Cancer Res. Clin. Oncol. 2007, 133:835-840.
41. Begley L.A., Kasina S., Mehra R., Adsule S., Admon A.J., Lonigro R.J., Chinnaiyan A.M., Macoska J.A. CXCL5 promotes prostate cancer progression. Neoplasia 2008, 10:244-254.
42. Wong Y.F., Cheung T.H., Lo K.W., Yim S.F., Siu N.S., Chan S.C., Ho T.W., Wong K.W., Yu M.Y., Wang V.W., Li C., Gardner G.J., Bonome T., Johnson W.B., Smith D.I., Chung T.K., Birrer M.J. Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene 2007, 26:1971-1982.
43. Miyazaki H., Patel V., Wang H., Edmunds R.K., Gutkind J.S., Yeudall W.A. Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res. 2006, 66:4279-4284.
44. Speetjens F.M., Kuppen P.J., Sandel M.H., Menon A.G., Burg D., van de Velde C.J., Tollenaar R.A., de Bont H.J., Nagelkerke J.F. Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin. Cancer Res. 2008, 14:2276-2284.
45. Li A., King J., Moro A., Sugi M.D., Dawson D.W., Kaplan J., Li G., Lu X., Strieter R.M., Burdick M., Go V.L., Reber H.A., Eibl G., Hines O.J. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am. J. Pathol. 2011, 178:1340-1349.
46. Hofmann J.J., Luisa Iruela-Arispe M. Notch expression patterns in the retina: an eye on receptor-ligand distribution during angiogenesis. Gene Expr. Patterns 2007, 7:461-470.
47. Reedijk M., Odorcic S., Chang L., Zhang H., Miller N., McCready D.R., Lockwood G., Egan S.E. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005, 65:8530-8537.
48. Simon D.P., Giordano T.J., Hammer G.D. Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma. Clin. Cancer Res. 2012, 18:2452-2464.
49. Trewick S.C., McLaughlin P.J., Allshire R.C. Methylation: lost in hydroxylation?. EMBO Rep. 2005, 6:315-320.
50. Takeuchi T., Yamazaki Y., Katoh-Fukui Y., Tsuchiya R., Kondo S., Motoyama J., Higashinakagawa T. Gene trap capture of a novel mouse gene, jumonji, required for neural tube formation. Genes Dev. 1995, 9:1211-1222.
51. Balciunas D., Ronne H. Evidence of domain swapping within the jumonji family of transcription factors. Trends Biochem. Sci. 2000, 25:274-276.
52. Clissold P.M., Ponting C.P. JmjC: cupin metalloenzyme-like domains in jumonji, hairless and phospholipase A2beta. Trends Biochem. Sci. 2001, 26:7-9.
53. Black J.C., Allen A., Van Rechem C., Forbes E., Longworth M., Tschop K., Rinehart C., Quiton J., Walsh R., Smallwood A., Dyson N.J., Whetstine J.R. Conserved antagonism between JMJD2A/KDM4A and HP1gamma during cell cycle progression. Mol. Cell 2010, 40:736-748.
54. Kauffman E.C., Robinson B.D., Downes M.J., Powell L.G., Lee M.M., Scherr D.S., Gudas L.J., Mongan N.P. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol. Carcinog. 2011, 50:931-944.
55. Kim T.D., Shin S., Berry W.L., Oh S., Janknecht R. The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J. Cell. Biochem. 2012, 113:1368-1376.
56. Li B.X., Luo C.L., Li H., Yang P., Zhang M.C., Xu H.M., Xu H.F., Shen Y.W., Xue A.M., Zhao Z.Q. Effects of siRNA-mediated knockdown of jumonji domain containing 2A on proliferation, migration and invasion of the human breast cancer cell line MCF-7. Exp. Ther. Med. 2012, 4:755-761.
57. Li B.X., Zhang M.C., Luo C.L., Yang P., Li H., Xu H.M., Xu H.F., Shen Y.W., Xue A.M., Zhao Z.Q. Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro. J. Exp. Clin. Cancer Res.: CR 2011, 30:90.
58. Mallette F.A., Richard S. JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. Cell Rep. 2012, 2:1233-1243.